OBIO announces Dr. Maura Campbell as Chair of its Board of Directors

– CANADA, Toronto –  OBIO today announced the appointment of Dr. Maura Campbell, VP, Intellectual Property and Contracts, Turnstone Biologics,  as Chair of the Board of Directors.

“I am very pleased to have a leader of Maura’s calibre and experience as the Chair of the OBIO Board of Directors,” said CEO, Gail Garland. “Maura is the first female Board Chair at OBIO and her depth of knowledge, her track record in the health science industry, and her energy all make her uniquely positioned to help guide OBIO as we continue to build the health science industry.

She added: “Over the past 12 months, OBIO has launched the Early Adopter Health Network, published two industry-leading reports on the state of the health science industry including Leading the Pack: Accelerating the Success of the Canadian Health Science Industry, and held the 2021 OBIO Investment Summit which featured over 80 global investors and over 50 companies from across Canada.”

About Dr. Maura Campbell

Dr. Maura Campbell is Vice President, Intellectual Property and Contracts at Turnstone Biologics. Maura has spent more than 30 years in technology transfer and the management and commercialization of intellectual property. She has business management experience in all key sectors of biotech, including private and public companies, universities and research institutes, and government-funded public sector research organizations (National Centre of Excellence).

Maura helped spin out Turnstone Biologics from IP developed at three Ontario academic institutes in 2015. Maura has had an active role in the Company’s Series A, B, and C financing, raising a total of over $90 million (U.S.). Previously, Maura was with VBI Vaccines where she served as Director, Intellectual Property. Before this, she was with the Ottawa Hospital Research Institute as a Senior Research Program Manager, where she oversaw the oncolytic vaccine project commercialization.

Earlier in her career, Maura was the Director of Intellectual Property for PainCeptor Pharma Corporation, the Manager of Technology Transfer & Commercialization for the OHRI, and the Manager of Technology Transfer at the Institute for Robotics and Intelligent Systems NCE. She has also served as an IP consultant to several Canadian start-ups including Neurochem, Conjuchem, Aonix, AMRIC, and Sussex Research Labs.

“I am honored to join OBIO as the Chair of the Board of Directors,” said Dr. Maura Campbell. “I am excited to bring my experience in technology transfer and the management and commercialization of intellectual property to help further OBIO’s success,” said Dr. Campbell. “As a thought-leading organization, OBIO’s work is truly building the health science industry and it is my privilege to be a part of OBIO’s efforts to support technology commercialization, workforce development, and market acceleration in health science industry.”

Maura received a Ph.D. in biochemistry from the University of Ottawa, and an M.Sc. and a B.Sc. in biochemistry from Queen’s University in Kingston.

About OBIO

The Ontario Bioscience Innovation Organization founded in 2009, is a not-for-profit, membership-based organization engaged in strategy, programming, policy development, and advocacy to further the commercialization of Ontario’s human health technologies positioning Ontario as a leader in the international marketplace. OBIO advances this goal through collaborative partnerships with industry, the investment community, academia, the health system, and the government.

For more information: https://www.obio.ca/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.